Yasunari Kashihara
Director/Board Member bij ONCOLYS BIOPHARMA INC.
Vermogen: 599 524 $ op 31-03-2024
Profiel
Yasunari Kashihara is currently the Director & Head-Business Development at Oncolys BioPharma, Inc., Director at Unleash Immuno Oncolytics, Inc., Director at Precision Virologics, Inc., Director at Oncolys USA, Inc., and President at Liquid Biotech USA, Inc. He previously held positions as President & Chief Executive Officer at UMN Pharma, Inc., Licensing Manager at Santen Pharmaceutical Co., Ltd., and Pharmacological Researcher at Ciba-Geigy Japan Ltd.
He obtained an MBA from Trinity College Dublin in 2002 and completed undergraduate and graduate studies at Kyoto University.
He also graduated from Kyoto Pharmaceutical University in 1991 and Osaka Prefectural Semboku High School in 1984.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ONCOLYS BIOPHARMA, INC.
0.57% | 31-12-2022 | 115 000 ( 0.57% ) | 599 524 $ | 31-03-2024 |
Actieve functies van Yasunari Kashihara
| Bedrijven | Functie | Begin |
|---|---|---|
| ONCOLYS BIOPHARMA INC. | Director/Board Member | 01-03-2008 |
Precision Virologics, Inc.
 Precision Virologics, Inc. BiotechnologyHealth Technology Precision Virologics, Inc. develops biologically targeted vaccines for emerging infectious diseases. The company was founded by David T. Curiel in 2017 and is headquartered in Saint Louis, MO. | Director/Board Member | 01-04-2017 |
Liquid Biotech USA, Inc.
 Liquid Biotech USA, Inc. Medical/Nursing ServicesHealth Services Liquid Biotech USA, Inc. provides cancer diagnosing services. The private company is based in Philadelphia, PA. | President | 01-11-2017 |
Unleash Immuno Oncolytics, Inc.
 Unleash Immuno Oncolytics, Inc. BiotechnologyHealth Technology Unleash Immuno Oncolytics, Inc. develops oncolytic virus immunotherapy products to treat cancer. Its product is UIO-512. the company is headquartered in Saint Louis, MO. | Director/Board Member | 01-02-2018 |
| Oncolys USA, Inc. | Director/Board Member | 01-01-2020 |
Eerdere bekende functies van Yasunari Kashihara
| Bedrijven | Functie | Einde |
|---|---|---|
| SANTEN PHARMACEUTICAL CO., LTD. | Corporate Officer/Principal | - |
| Ciba-Geigy Japan Ltd. | Corporate Officer/Principal | - |
| UMN PHARMA INC. | President | - |
Opleiding van Yasunari Kashihara
| Trinity College Dublin | Masters Business Admin |
| Kyoto University | Graduate Degree |
| Kyoto Pharmaceutical University | Graduate Degree |
| Osaka Prefectural Semboku High School | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SANTEN PHARMACEUTICAL CO., LTD. | Health Technology |
| ONCOLYS BIOPHARMA INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
UMN Pharma, Inc.
 UMN Pharma, Inc. Pharmaceuticals: MajorHealth Technology UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It operates through a following business division: Next-generation biopharmaceutical in-house development business and Biopharmaceutical contract manufacturing business. The Next-generation biopharmaceutical in-house development business engages in the research and development of next-generation logical vaccine by integrating next-generation biopharmaceutical drug substance manufacturing technology, adjuvant technology and drug delivery technology. The Biopharmaceutical contract manufacturing business offers study samples, investigational drugs, products, and various evaluation test results. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan. | Health Technology |
| Ciba-Geigy Japan Ltd. | |
Unleash Immuno Oncolytics, Inc.
Unleash Immuno Oncolytics, Inc. BiotechnologyHealth Technology Unleash Immuno Oncolytics, Inc. develops oncolytic virus immunotherapy products to treat cancer. Its product is UIO-512. the company is headquartered in Saint Louis, MO. | Health Technology |
Precision Virologics, Inc.
Precision Virologics, Inc. BiotechnologyHealth Technology Precision Virologics, Inc. develops biologically targeted vaccines for emerging infectious diseases. The company was founded by David T. Curiel in 2017 and is headquartered in Saint Louis, MO. | Health Technology |
Liquid Biotech USA, Inc.
Liquid Biotech USA, Inc. Medical/Nursing ServicesHealth Services Liquid Biotech USA, Inc. provides cancer diagnosing services. The private company is based in Philadelphia, PA. | Health Services |
| Oncolys USA, Inc. |
